MedTrace Logo

Cardio-protective Effect of Metformin in Patients Undergoing PCI

NCT05708053 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2023-09-13

No results posted yet for this study

Summary

This is a two-arm randomized parallel study. Patients who will be meeting the above-mentioned criteria and agree to take part in the study, were asked to sign an informed consent prior conducting the study.

The whole study protocol were presented to the local institutional review board (IRB).

Conditions

  • Elective Percutaneous Coronary Intervention
  • Ischemic Reperfusion Injury

Interventions

DRUG

Metformin

Metformin 500 mg twice

Sponsors & Collaborators

  • Cairo University

    collaborator OTHER

  • Future University in Egypt

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-09
Primary Completion
2021-12-09
Completion
2024-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05708053 on ClinicalTrials.gov